

CMO360°

Chief Medical Officer Summit

April 3 - 4, 2023 | Boston Park Plaza, Boston, MA

2023 KEYNOTES AND SPECIAL GUEST



Jessica Chutter
Morgan Stanley



Tal Zaks, MD, PhD
OrbiMed



John Maraganore, PhD
Alnylam Pharmaceuticals



Elena Lovo, PhD
JP Morgan



Elizabeth Stoner, MD
MPM Capital



Kenneth Getz, MBA
Tufts CSDD

Lead Sponsor



Featured Executive Sponsors



DAY ONE - MONDAY, APRIL 3, 2023

7:50 am

Registration Opens, Tea/Coffee

8:20 am

Co-Chairs Opening Remarks

Nerissa Kreher, MD, MBA
CMO, Entrada Therapeutics

Ed Tucker, MD, MBA
Former CMO, Goldfinch Bio

8:30 am

ANNUAL KEYNOTE

Annual Clinical Development Landscape Keynote

- Overview of the changing drug development landscape
- Review of underlying trends and practices and their current and anticipated impact
- Discuss strategies and practices addressing challenges and pain points
- Highlight transformational opportunities to optimize drug development performance



Kenneth Getz, MBA

Executive Director and Professor, Tufts Center for the Study of Drug Development,
Tufts University School of Medicine/ Founder and Board Chair, CISCRP

9:00 am

CEO KEYNOTE

Reflections on Alnylam and Biotech Leadership

The CMO Summit is honored to have for the first time, bioentrepreneur, Dr John Maraganore, founding CEO, Alnylam Pharmaceuticals, as a keynote presenter. Dr Maraganore will share highlights and lessons learned from his 19 years as a CEO leading a team that conquered some very difficult drug development challenges.



John Maraganore, PhD

Founding CEO
Alnylam Pharmaceuticals

9:30 am

FINANCIAL ANALYST KEYNOTE

Keynote Fireside Discussion with JP Morgan Executive Director of Healthcare Investment Banking

In this fireside discussion, Dr Elena Lovo shares her thoughts on:

- Biotech investment trends in 2023
- What American biotechs should consider about the European biotech finance environment
- How CMOs can support the overarching process of a fundraising
- The hard and soft skills needed to succeed in investor interactions



Elena Lovo, PhD

Executive Director, Healthcare
Investment Banking, JP Morgan



with

Nerissa Kreher, MD, MBA

CMO, Entrada Therapeutics

10:00 am**Grand Opening of the CMO Summit 360° Cafe & Networking Break**

- Breakfast
- Meet the Exhibitors
- Peer-to-Peer Meetings

**10:45 am****An Update on Regulatory Trends and Best Practices in Navigating FDA Interactions****Moderated by:****Anna Berkenblit, MD, MMSc**
*VP, CMO, ImmunoGen***Panelists:****Matteo Levisetti, MD**
*CMO, Cue Biopharma***Laurie Smaldone, MD**
*Chief Medical & Scientific Officer, NDA Group***Laura Williams, MD, MPH**
*CMO, Ardelyx***Scott Harris, MD**
*CMO, Altimune***11:15 am****Leveraging Patient Advocacy Groups for Successful Trial Recruitment**

- Provide an educational experience and build knowledge to help patients decide to enroll into clinical trials
- Overcoming lack of diversity in clinical trials by directly reaching out the patient communities

Andreas Reiff, MD
*SVP, Immunology & Inflammation, Parexel***11:30 am****Regulatory Case Study: Getting FDA Approval in a Cell & Gene Therapy****Richard Colvin, MD, PhD**
*CMO, Bluebird Bio***11:50 am****Strategies to Design Development Plans for Adoption, Access and Approval**

In this session, Dr Murphy shares strategies to design clinical development plans that incorporate a mix of observational and interventional research to address divergent needs for data in order to facilitate adoption, access and approval, including:

- Demonstrating “value,” efficacy and safety
- Tailoring your approach to different phases of development and with diverse stakeholders in mind
- How to best leverage Clinical Research Organizations to facilitate this process

Michael Murphy, MD, PhD
*Chief Medical & Scientific Officer, Worldwide Clinical Trials***12:05 pm****Prioritizing Development Programs and Pipelines that Align with Fundraising Catalysts**

In this session, panelists discuss how they prioritize and optimize their development portfolios for success and make development decisions in the current resource-constrained environment. Should you prioritize assets with the best quality science? Lowest cost? Fastest? Biggest ROI?

Moderated by:**Bernard Ravina, MD, MS**
*Entrepreneur in Residence, Atlas Venture***Panelists:****Albert Kim, MD, PhD**
*CMO, Cytel***Mustafa Noor, MD**
*CMO, Olatec Therapeutics***Mauro Avanzi, MD, PhD**
CMO, Shoreline Biosciences

12:35 pm

Getting Hard Feasibility Data: How To Do It

This presentation offers key insights with answers that speak to the following:

- How do you access current, hard feasibility data?
- Does your CRO have a stable, permanent clinical team with trial legacy capability and expertise in your domain?
- Are your sites and vendors audit proof?
- Does your CRO act like a SMO with a dedicated site network?
- Are you confident your CRO has the capacity to achieve your study milestones on or before deadline?
- Is your CRO independent, and well-rounded in regard to systems, with a collaborative vendor team of specialized expertise to support your program?

Patrick Smith, MSc

Feasibility Manager & Clinical Trial Leader,
Scimega Research

12:50 pm

CMO Summit Founding Advisor on the Biotech Landscape

Dr Stoner shares her thoughts on the biotech investment landscape and what investors look for in a CMO.

Elizabeth Stoner, MD

Executive Partner, **MPM Capital**

1:00 pm

Lunch and Optional Roundtable Discussions

- Lunch
- Meet the Exhibitors
- Peer-to-Peer Meetings

For those of you joining a roundtable, please get your lunch and make your way to your roundtable of choice at 1:20pm.

Roundtables require an RSVP. If you have not secured your spot, please see the registration desk.

**Optional Roundtable Discussions****Roundtable #1:
Challenges & Opportunities in CNS**

Shaheen Lakhan, MD, PhD
CMO, Click Therapeutics

Richard Malamut, MD
CMO, MedinCell

Timothy Peters-Strickland, MD
VP, Global Medical Officer, Biotech Solutions, PPD, Part of Thermo Fisher Scientific

**Roundtable #2:
New Regulatory Initiative in Oncology**

Alessandra Cesano, MD, PhD
CEO, ESSA Pharma

Kartik Krishnan, MD, PhD
CMO, OncoNano Medicine

**Roundtable #3:
Challenges & Opportunities in Cell & Gene Therapy**

Todd Druley, MD, PhD
CMO, Mission Bio

Mohammed Asmal, MD
SVP, Head of Clinical, Prime Medicine

**Roundtable #4:
Challenges & Opportunities in Rare Disease**

Ottavio Vitolo, MD
CMO, Cerevance

Raymond Urbanski, MD, PhD
SVP, Head of Clinical Development & Medical Affairs, PharmaEssentia

2:00 pm Two Track Choices	
TRACK A: Early Stage Companies / Development	TRACK B: Late Stage Development / Medical Affairs
Track Chair: Anna Frostegård, MD, PhD <i>Co-Founder, Chief Scientific & Medical Officer,</i> Annexin Pharmaceuticals	Track Chair: Ed Tucker, MD, MBA <i>Former CMO</i> Goldfinch Bio
2:00 pm What CMOs Get Right and Get Wrong About Early Development Barry Ticho, MD, PhD <i>CMO, Stoke Therapeutics</i> David Davidson, MD <i>Chief Medical & Development Officer,</i> Tessera Therapeutics	2:00 pm Preparing for Late-Stage Development Seemi Khan, MD, MPH, MBA <i>SVP, CMO, Reata Therapeutics</i>
2:20 pm Intro to Finance & IPOs for CMOs <p>The financial side of leading a biotech can often seem like a different language to CMOs. In this session, panelists representing the CMO, CFO, investor and analyst perspectives explain what CMOs need to know about the IPO process from drafting an S-1 through bake-offs, TTWs, pitch deck drafting, the roadshow and stock issuance.</p> <p>Moderated by:</p> <p>Joanne Lager, MD <i>CEO, iTeos Therapeutics</i></p> <p>Panelists:</p> <p>Timothy Lu, MD, PhD <i>CEO, Dice Therapeutics</i></p> <p>Josh Schimmer, MD, MBA <i>Senior Managing Director, Evercore ISI</i></p> <p>Sanjay Subramanian, MS, MBA <i>CFO, Inozyme Pharma</i></p> <p>Bernard Cooney, MBA <i>Senior Partner, Capital Formation</i> Flagship Pioneering</p>	2:20 pm Interacting with Different Types of Investors as a CMO <p>In a constrained financial environment, presenting effectively to investors and analysts becomes paramount. In this session, panelists discuss how best to interact with specialist and generalist investors and analysts. Topics include:</p> <ul style="list-style-type: none"> • Tailoring your message to bulls and bears • What do you do if they don't believe in your company? • What types of data are investors looking for? • What exasperates investors and analysts about biotechs and how to rise above <p>Moderated by:</p> <p>Alex Snyder, MD <i>CMO, Generate Biosciences</i></p> <p>Panelists:</p> <p>Jatin Shah, MD <i>CMO, EVP and Global Head of Development,</i> Sumitomo Pharma Oncology</p> <p>Randall Stanicky <i>CFO, Click Therapeutics</i></p> <p>Timothy Peters-Strickland, MD <i>VP, Global Medical Officer, Biotech Solutions</i> PPD, Part of Thermo Fisher Scientific</p> <p>Stefan Vitorovic, MS, MBA <i>Co-Founder & Managing Director, Vida Ventures</i></p>

TRACK A:	TRACK B:
3:00 pm Developing Internal and External Communication Strategies <p>In this panel, perspectives from corporate communications, CMOs and CEOs discuss best practices in effectively sharing your story with different audiences focusing on:</p> <ul style="list-style-type: none"> • Authentic messaging • Press releases • Sharing new data • Social media • Managing bad news <p>Moderated by:</p> <p>Jodie Gillon, MPH <i>SVP, Corporate Affairs & Patient Advocacy, Peptilogics</i></p> <p>Panelists:</p> <p>Karla MacDonald <i>Chief Corporate Affairs Officer, Entrada Therapeutics</i></p> <p>Austin Chiang, MD, MPH <i>CMO, Medtronic GI</i></p> <p>Stephen Kanes, MD, PhD <i>CEO, EmbarkNeuro</i></p> <p>Daniel Gold <i>President, Fairway Consulting Group</i></p>	3:00 pm What CMOs Need to Know About Medical Affairs <ul style="list-style-type: none"> • Publication management • Internal interactions • KOL interactions • Working with MSL organizations • When to officially kick off medical affairs <p>Moderated by:</p> <p>John Yee, MD, MPH <i>CMO, Sobi – North America</i></p> <p>Panelists:</p> <p>Daniel Chung, DO, MA <i>CMO, SparingVision</i></p> <p>Joseph Ellassal, MD, MBA <i>CMO, Ankyra Therapeutics</i></p> <p>Peg Crowley-Nowick, PhD, MBA <i>President, Medical Affairs Consulting and Head of Medical Affairs, Lumanity</i></p>

3:30 pm Afternoon Ice Cream Break & Networking

- Refreshments with Social Distance
- Meet the Exhibitors
- Peer-to-Peer Meetings



4:00 pm Two Track Choices	
TRACK A: Innovations in Clinical Development & Remote Work	TRACK B: Outsourcing & Workforce Development
<p>Track Chair:</p> <p>Anna Frostegård, MD, PhD <i>Co-Founder, Chief Scientific & Medical Officer, Annexin Pharmaceuticals</i></p>	<p>Track Chair:</p> <p>Ed Tucker, MD, MBA <i>Former CMO, Goldfinch Bio</i></p>

TRACK A:	TRACK B:
<p>4:00 pm Implementing Patient-Centricity Throughout Clinical Development and Preparing for Launch</p> <p>This session provides CMOs with updated trends and best practices to avoid pitfalls and maximize collaboration throughout the development continuum to benefit patients and caregivers, the trial and the biotech. Specifically:</p> <ul style="list-style-type: none"> • Protocol development, trial execution • Preparing for reimbursement at launch • Novel ways to engage patients and caregivers • Patient fair market value • Trial endpoint decisions <p>Moderated by:</p> <p>Serena Hung, MD CMO, Arkuda Therapeutics</p> <p>Panelists:</p> <p>Rolf Benirschke Patient Advocate & Former NFL Player, Legacy Health Strategies</p> <p>Sarah Gheuens, MD, PhD, MMSc CMO, Head of R&D, Agios Pharmaceuticals</p> <p>Amy Simon, MD CMO, Beam Therapeutics</p>	<p>4:00 pm CRO Selection & Assigning Accountability</p> <p>Arguably the most important and expensive decision a biotech makes is around choosing a development partner. In this session, CMOs and CROs share how to navigate the RFP process in selecting a partner as well as how to avoid costly change orders and prevent common pitfalls.</p> <p>Moderated by:</p> <p>Edwin Rock, MD, PhD CMO, GlycoMimetics</p> <p>Panelists:</p> <p>David Huang, MD, PhD SVP & CMO, Peptilogics</p> <p>Raul Lima, MBA EVP, Strategic Clinical Operations, inSection Group</p>
<p>4:30 pm Clinical Trials Outside the Office: DCTs and RWE in 2023 and Beyond</p> <p>Panelists share experiences and best practices in designing and running decentralized clinical trials focusing on:</p> <ul style="list-style-type: none"> • Ensuring data integrity and patient safety • Usability for sites & patients • Changing regulatory implications • Empowering patients • Justifying the investment in these technologies and models <p>Moderated by:</p> <p>Jeffrey Bornstein, MD CMO, Eledon Pharmaceuticals</p> <p>Panelists:</p> <p>Joseph Kim, MBA Chief Strategy Officer, ProofPilot</p> <p>Ali Hariri, MD SVP, CMO, Eloxx Pharmaceuticals</p> <p>Chelsey Ryan Director of Clinical Operations and Pharmacovigilance, PROMETRIKA</p>	<p>4:30 pm Best Practices in Building Out Your Clinical Development Team</p> <p>This session addresses the following key issues:</p> <ul style="list-style-type: none"> • How do you incorporate FTEs, consultants and CROs as your company grows? • What are the pivot points around which you hire in-house expertise? • How do you think about partnering with boutique CROs versus the big box CROs? • How do finances tie into these decisions? <p>Moderated by:</p> <p>Vicki Goodman, MD CMO, Exelixis</p> <p>Panelists:</p> <p>Marcella Ruddy, MD CMO, Tectonic Therapeutic</p> <p>Hunter Smith Executive Recruiter, Govig & Associates</p> <p>Raul Lima, MBA EVP, Strategic Clinical Operations, inSection Group</p>

TRACK A:	TRACK B:
<p>5:00 pm Leading & Managing Hybrid Teams</p> <p>As companies have more time to thoughtfully explore evolving work environments, building and maintaining a corporate culture with an eye towards flexibility becomes both an opportunity to attract and retain talent and a challenge to manage geographically diverse teams. Panelists address:</p> <ul style="list-style-type: none"> • Different models of virtual and hybrid work • Investing in corporate culture to ensure unity of mission • Impacts on hiring practices, career development, retention and operations • Lessons learned <p>Moderated by:</p> <p>Simon Cooper, MBBS CMO, Keros Therapeutics</p> <p>Panelists:</p> <p>Christophe Arbet-Engels, MD, PhD, MBA CMO, Neurogastrx</p> <p>Karen Ivester Executive Director Operations, Cell & Gene Therapy Programs, inSection Group</p> <p>Nushmia Khokhar, MD CMO, Pyramid Biosciences</p>	<p>5:00 pm Navigating the Urgent Workforce Shortage and Turnover</p> <p>With the growing trend of employees moving from company to company, the difficult financial environment and increased specialization of roles within biotech, effectively hiring and retaining staff is a top priority. Panelists discuss:</p> <ul style="list-style-type: none"> • Running operations effectively considering all the movement • Hiring the right people quickly without selling yourself short • Managing for title and salary creep • Retaining talent through non-monetary incentives <p>Moderated by:</p> <p>Patrick Burnett, MD, PhD CMO, Arcutis Biotherapeutics</p> <p>Panelists:</p> <p>Barbara Day Principal, Pharmaceutical Practice, Penfield Search Partners</p> <p>Holly Schachner, MD SVP, Clinical Development, NorthSea Therapeutics</p> <p>James Lewis Executive Director, Barrington James</p> <p>Cliff Miras Managing Partner, Miras Search Partners</p>

5:30 pm
Networking Reception

6:30 pm
Day One Ends



DAY TWO - TUESDAY APRIL 4, 2023

7:50 am

Registration Opens, Tea/Coffee

8:20 am

Co-Chairs Opening Remarks

Nerissa Kreher, MD, MBA

CMO, Entrada Therapeutics

Ed Tucker, MD, MBA

Former CMO, Goldfinch Bio

8:30 am

BIOTECH INVESTMENT BANKING KEYNOTE

Keynote Fireside Discussion with Morgan Stanley's Managing Director and Chair of Biotechnology Investment Banking

In this fireside chat, we are pleased to welcome back Jessica Chutter to share her thoughts on:

- The current state of the biotech financial environment
- Future of biotech M&A
- Trends, opportunities
- Thoughts on evaluating companies
- Strategic transactions
- Examples of how investors evaluate companies
- Thoughts on sustaining publicly traded companies
- The importance of clinical trial design and readouts
- Thoughts on regulatory pathways, and primary endpoints
- Q&A



Jessica Chutter

Managing Director and Chair of Biotechnology Investment Banking, **Morgan Stanley**

with



Alise Reicin, MD

CEO & President, **Tectonic Therapeutic**

9:00 am

CMO KEYNOTE

The Evolving CMO Role Through Moderna's Rapid Development

In this session, Dr Zaks will share how he adapted his role as CMO at Moderna through rapid vaccine development from pre-clinical through commercialization in an unprecedented time. He will also discuss views on the future of biotech drug development.



Tal Zaks, MD, PhD

Partner, Private Equity, **OrbiMed**

9:30 am

Visualizing Trade-Offs and Improving Decision-Making

This talk will discuss mitigation strategies to manage uncertainties improve decision-making in clinical development, with a focus on:

- Difficult choice of endpoints (multiple candidates) and study population
- Enabling better interim decisions
- Visualizing trade-offs to inform decisions

Natalia “Natasha” Mühlemann, MD, MBA*VP, Strategic Consulting, Cytel*

9:50 am

Morning Break & Networking

- Breakfast
- Meet the Exhibitors
- Peer-to-Peer Meetings



10:30 am

C-SUITE FIRESIDE CHATS

For the first time at the Summit, CMOs are joined by their C-Suite colleagues in fireside discussions to share how CMOs can best engage with their peers, overcome pain points, agree and disagree effectively and collaborate cross-functionally.

CMO – COO**Mark De Rosch, PhD***COO, Aura Biosciences***Cadmus Rich, MD***CMO & Head of R&D, Aura Biosciences***CMO – CFO****Richard Wanstall, MBA***CFO, Oncorus***John Goldberg, MD***CMO, Oncorus***CMO – CSO****Philip Ashton-Rickardt, PhD***CSO, Sigilon Therapeutics***May Orfali, MD, MBA***EVP, CMO, Sigilon Therapeutics*

11:30 am

Crash Courses on Topics Every CMO Should Learn About:

Patient Adherence, Global Regulatory Strategy, Quality Assurance & Pharmacometrics

Moderated by:

Ed Tucker, MD, MBA

Former CMO, Goldfinch Bio

Lessons Learned in Implementing Digital Adherence Monitoring in a Late-Stage Drug Development Clinical Trial

- An introduction to the ramifications of poor adherence in clinical trials
- Tell-tale signs that poor adherence is present
- People, process, and tech involved in digital monitoring implementation
- Lessons Learned

Bernard Vrijens, PhD

CEO & Scientific Lead, AARDEX Group

Ning Yu, PhD, MBA

Director, Technical Development, Biogen

Implementing Digital Adherence Monitoring in a Late-Stage Drug Development Clinical Trial

- Application of early regulatory engagement in Europe & UK
- Benefits of regulatory alignment across EMA, FDA & UK
- Building your PV, QA & REG teams at the right time

Peter Embley

Chief Regulatory Officer, Ariello

Establishing a Culture of Quality: What Every CMO Must Know

- Five key elements of a culture of quality
- Four strategies for enabling a culture of quality
- Three risks of not adopting a culture of quality
- Positive business impact of a culture of quality

Sheila Gwizdak, MS

VP, Organizational and Quality Solutions, Halloran Consulting Group

Exposure-Response Analysis to Find the Right Dose for the Right Patient

The key to successful drug development is finding the drug exposure that maximizes efficacy and minimizes side effects. Pharmacometrics integrates complex pharmacological and biological information from various sources into exposure-response models. This session will address how CMOs can leverage highly skilled pharmacometricians and clinical pharmacologists to create actionable insights for making informed dose decisions, including:

- Finding the right dose for the general patient population and special populations using exposure-response models
- Utilizing these regulatory compliant analyses at all stages of drug development.
- Leveraging these tools to improve the probability of success throughout the drug development process.

Klaas Prins, PhD

Head of Business Development & Partner, qPharmetra

12:30 pm

M&A From the CMO Perspective

In this session, panelists share their experiences as CMOs leading up to and during mergers. They specifically address:

- How to frame yourself for pharma and when to approach them
- Fostering a great relationship and balancing priorities
- Avoiding negative outcomes including delays and loss of knowledge
- What's next for CMOs

Moderated by:

Barbara Klencke, MD

CMO, Sierra Oncology, a GSK Company

Panelists:

Howard Rutman, MD, MBA

CMO, Xalud Therapeutics

Tadaaki Taniguchi, MD, PhD

CMO, Astellas Pharma

1:00 pm Lunch and Optional Roundtable Discussions

- Lunch
- Meet the Exhibitors
- Peer-to-Peer Meeting

For those of you joining a roundtable, please get your lunch and make your way to your roundtable of choice at 1:20 pm. Roundtables require an RSVP. If you have not secured your spot, please see the registration desk.

<p>Roundtable #1: Adapting to the Role as a First-Time CMO</p> <p>Raphaël Rousseau, MD, PhD Former CMO, Neogene Therapeutics</p> <p>Chin Lee, MD, MPH CMO, Connect Biopharma</p>	<p>Roundtable #2: Compensation Contracting 101 for CMOs</p> <p>Navigating CMO Compensation and Negotiations</p> <p>Joseph Palumbo, MD, MACPsych CMO, BioVie</p> <p>Hunter Smith Executive Recruiter, Govig & Associates</p> <p>Donna Higgins CEO, The Higgins Group</p>	<p>Roundtable #3: Career Coaching for CMOs</p> <p>Roger Waltzman, MD, MBA CMO, Molecular Templates</p> <p>Debora Barton, MD CMO, TScan Therapeutics</p>	<p>Roundtable #4: Making an Impact Through Storytelling</p> <p>Effective storytelling is the key to attracting investors and motivating employees. In this roundtable discussion, presentation coach Donna Schwarz will provide a framework to quickly convey a compelling story that influences and inspires.</p> <p>Donna Schwarz Presentation Coach, Schwarz Consultants</p>
--	--	---	---

2:00 pm

Unexpected Skill Sets Needed to Succeed as a CMO

CMOs share what skills they had, what they needed to learn and how they figured out the unknown unknowns based on their backgrounds in academia, pharma or biotech.

Moderated by:

James "Terry" Ferguson, MD

CMO, Matinas Biopharma

Panelists:

Sarah Grant, MD

CMO, Celsius Therapeutics

Arvin Yang, MD, PhD

CMO, Mersana Therapeutics

Deyaa Adib, MD

CMO, Triumvira Immunologics

Donna Higgins

CEO, The Higgins Group

2:30 pm**Navigating Board Interactions from Startup through Commercialization**

In this session, CMOs and board members share how to best have influence and communicate simply and effectively with your Board around development, regulatory pathways, and justifying spending. Additionally, they discuss best practices around evolving boards, hiring/firing board members and independent board members.

Moderated by:**Randall Kaye, MD, MPH***CMO, Longboard Pharmaceuticals***Panelists:****Elliot Ehrich, MD***CMO, EVP, Translational Science, LifeMine Therapeutics***Iman El-Hariry, MD, PhD***CMO, Erytech***Michele Gerber, MD, MPH***CMO, Myeloid Therapeutics***Mary Spellman, MD***Principal, Panclarity***3:00 pm****Gathering Expertise in New Indications and Modalities**

Over the course of one's career as a CMO, there is inevitably exposure to new indications or modalities of treatment whether as one transitions from company to company or as a biotech expands its asset and study portfolio. In this session, panelists share how they achieved competence and expertise in new areas as well as best practices in leveraging external experts.

Moderated by:**Alessandra Cesano, MD, PhD***CMO, ESSA Pharma***Panelists:****Samuel Falsetti, PhD***Global Chief Biotechnology & Innovative Solutions Officer, Inizio Biotech***Barbara Wirostko, MD***CMO & Co-Founder, Qlaris Bio***3:30 pm****The CMO's Role as Mentor**

In addition to the CMO's responsibilities as an executive within their company, there is also a desire to provide mentorship and growth opportunities to both direct and indirect reports. In this session, panelists share how they think about and provide professional development to their teams.

Moderated by:**Barbara Troupin, MD***Independent Director, Equillum***Panelists:****Eslie Dennis, MD, MBChB***SVP, CMO & Head NA Medical Affairs, Kyowa Kirin***David Feltquate, MD, PhD***CMO, Palleon Pharmaceuticals***Oscar Segurado, MD, PhD***CMO, ASC Therapeutics***4:00 pm****Town Hall on CMO Career Development****Steve Zelenkofske, DO***President/Principal, SLZ Consulting***Randall Moreadith, MD, PhD***President & CEO, Serina Therapeutics***4:30 pm****Conference Concludes**